Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 43 entries
Sorted by: Best Match Show Resources per page
Identification of human serum peptides in fourier transform ion cyclotron resonance precision profiles.

International journal of proteomics

Nicolardi S, Dalebout H, Bladergroen MR, Mesker WE, Tollenaar RA, Deelder AM, van der Burgt YE.
PMID: 22685657
Int J Proteomics. 2012;2012:804036. doi: 10.1155/2012/804036. Epub 2012 May 22.

The continuous efforts to find new prognostic or diagnostic biomarkers have stimulated the use of mass spectrometry (MS) profiles in a clinical setting. In the early days (about one decade ago), a single low-resolution mass spectrum derived from an...

Cite
Nicolardi S, Dalebout H, Bladergroen MR, et al. Identification of human serum peptides in fourier transform ion cyclotron resonance precision profiles. Int J Proteomics. 2012;2012:804036doi: 10.1155/2012/804036.
Nicolardi, S., Dalebout, H., Bladergroen, M. R., Mesker, W. E., Tollenaar, R. A., Deelder, A. M., & van der Burgt, Y. E. (2012). Identification of human serum peptides in fourier transform ion cyclotron resonance precision profiles. International journal of proteomics, 2012804036. https://doi.org/10.1155/2012/804036
Nicolardi, Simone, et al. "Identification of human serum peptides in fourier transform ion cyclotron resonance precision profiles." International journal of proteomics vol. 2012 (2012): 804036. doi: https://doi.org/10.1155/2012/804036
Nicolardi S, Dalebout H, Bladergroen MR, Mesker WE, Tollenaar RA, Deelder AM, van der Burgt YE. Identification of human serum peptides in fourier transform ion cyclotron resonance precision profiles. Int J Proteomics. 2012;2012:804036. doi: 10.1155/2012/804036. Epub 2012 May 22. PMID: 22685657; PMCID: PMC3364581.
Copy Download .nbib Format: NLM
Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Doekhie FS, Morreau H, de Bock GH, Speetjens FM, Dekker-Ensink NG, Putter H, van de Velde CJ, Tollenaar RA, Kuppen PJ.
PMID: 19308692
Cancer Microenviron. 2008 Dec;1(1):141-51. doi: 10.1007/s12307-008-0014-3. Epub 2008 Aug 06.

Up to 30% of curatively resected colorectal cancer patients with tumor-negative lymph nodes, show disease recurrence. We assessed whether these high-risk patients can be identified by examining primary tumors for the following blood and lymphatic vasculature markers: A) sialyl...

Cite
Doekhie FS, Morreau H, de Bock GH, et al. Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence. Cancer Microenviron. 2008;1(1):141-51doi: 10.1007/s12307-008-0014-3.
Doekhie, F. S., Morreau, H., de Bock, G. H., Speetjens, F. M., Dekker-Ensink, N. G., Putter, H., van de Velde, C. J., Tollenaar, R. A., & Kuppen, P. J. (2008). Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 1(1), 141-51. https://doi.org/10.1007/s12307-008-0014-3
Doekhie, Fania S, et al. "Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence." Cancer microenvironment : official journal of the International Cancer Microenvironment Society vol. 1,1 (2008): 141-51. doi: https://doi.org/10.1007/s12307-008-0014-3
Doekhie FS, Morreau H, de Bock GH, Speetjens FM, Dekker-Ensink NG, Putter H, van de Velde CJ, Tollenaar RA, Kuppen PJ. Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence. Cancer Microenviron. 2008 Dec;1(1):141-51. doi: 10.1007/s12307-008-0014-3. Epub 2008 Aug 06. PMID: 19308692; PMCID: PMC2654349.
Copy Download .nbib Format: NLM
Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

Nature communications

Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van't Veer LJ, Rutgers EJT, Couch FJ, Olson JE, Hallberg E, Vachon C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Gibson L, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Noh DY, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Benitez J, Pilar Zamora M, Perez JIA, Menéndez P, Shu XO, Lu W, Gao YT, Cai Q, Cox A, Cross SS, Reed MWR, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Lindblom A, Margolin S, Teo SH, Yip CH, Lee DSC, Wong TY, Hooning MJ, Martens JWM, Collée JM, van Deurzen CHM, Hopper JL, Southey MC, Tsimiklis H, Kapuscinski MK, Shen CY, Wu PE, Yu JC, Chen ST, Alnæs GG, Borresen-Dale AL, Giles GG, Milne RL, McLean C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Buhari SABS, Teo YY, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Brauch H, Brüning T, Koto YD, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova NV, Helbig S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RAEM, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton-Culver H, Neuhausen SL, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Rosario Alonso M, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown MA, Lupien M, Kristensen VN, Pharoah PDP, Chenevix-Trench G, French JD, Easton DF, Dunning AM.
PMID: 29633761
Nat Commun. 2018 Apr 10;9:16193. doi: 10.1038/ncomms16193.

This corrects the article DOI: 10.1038/ncomms5999.

Cite
Ghoussaini M, Edwards SL, Michailidou K, et al. Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun. 2018;9:16193doi: 10.1038/ncomms16193.
Ghoussaini, M., Edwards, S. L., Michailidou, K., Nord, S., Cowper-Sal Lari, R., Desai, K., Kar, S., Hillman, K. M., Kaufmann, S., Glubb, D. M., Beesley, J., Dennis, J., Bolla, M. K., Wang, Q., Dicks, E., Guo, Q., Schmidt, M. K., Shah, M., Luben, R., Brown, J., Czene, K., Darabi, H., Eriksson, M., Klevebring, D., Bojesen, S. E., Nordestgaard, B. G., Nielsen, S. F., Flyger, H., Lambrechts, D., Thienpont, B., Neven, P., Wildiers, H., Broeks, A., Van't Veer, L. J., Rutgers, E. J. T., Couch, F. J., Olson, J. E., Hallberg, E., Vachon, C., Chang-Claude, J., Rudolph, A., Seibold, P., Flesch-Janys, D., Peto, J., Dos-Santos-Silva, I., Gibson, L., Nevanlinna, H., Muranen, T. A., Aittomäki, K., Blomqvist, C., Hall, P., Li, J., Liu, J., Humphreys, K., Kang, D., Choi, J. Y., Park, S. K., Noh, D. Y., Matsuo, K., Ito, H., Iwata, H., Yatabe, Y., Guénel, P., Truong, T., Menegaux, F., Sanchez, M., Burwinkel, B., Marme, F., Schneeweiss, A., Sohn, C., Wu, A. H., Tseng, C. C., Van Den Berg, D., Stram, D. O., Benitez, J., Pilar Zamora, M., Perez, J. I. A., Menéndez, P., Shu, X. O., Lu, W., Gao, Y. T., Cai, Q., Cox, A., Cross, S. S., Reed, M. W. R., Andrulis, I. L., Knight, J. A., Glendon, G., Tchatchou, S., Sawyer, E. J., Tomlinson, I., Kerin, M. J., Miller, N., Haiman, C. A., Henderson, B. E., Schumacher, F., Le Marchand, L., Lindblom, A., Margolin, S., Teo, S. H., Yip, C. H., Lee, D. S. C., Wong, T. Y., Hooning, M. J., Martens, J. W. M., Collée, J. M., van Deurzen, C. H. M., Hopper, J. L., Southey, M. C., Tsimiklis, H., Kapuscinski, M. K., Shen, C. Y., Wu, P. E., Yu, J. C., Chen, S. T., Alnæs, G. G., Borresen-Dale, A. L., Giles, G. G., Milne, R. L., McLean, C., Muir, K., Lophatananon, A., Stewart-Brown, S., Siriwanarangsan, P., Hartman, M., Miao, H., Buhari, S. A. B. S., Teo, Y. Y., Fasching, P. A., Haeberle, L., Ekici, A. B., Beckmann, M. W., Brenner, H., Dieffenbach, A. K., Arndt, V., Stegmaier, C., Swerdlow, A., Ashworth, A., Orr, N., Schoemaker, M. J., García-Closas, M., Figueroa, J., Chanock, S. J., Lissowska, J., Simard, J., Goldberg, M. S., Labrèche, F., Dumont, M., Winqvist, R., Pylkäs, K., Jukkola-Vuorinen, A., Brauch, H., Brüning, T., Koto, Y. D., Radice, P., Peterlongo, P., Bonanni, B., Volorio, S., Dörk, T., Bogdanova, N. V., Helbig, S., Mannermaa, A., Kataja, V., Kosma, V. M., Hartikainen, J. M., Devilee, P., Tollenaar, R. A. E. M., Seynaeve, C., Van Asperen, C. J., Jakubowska, A., Lubinski, J., Jaworska-Bieniek, K., Durda, K., Slager, S., Toland, A. E., Ambrosone, C. B., Yannoukakos, D., Sangrajrang, S., Gaborieau, V., Brennan, P., McKay, J., Hamann, U., Torres, D., Zheng, W., Long, J., Anton-Culver, H., Neuhausen, S. L., Luccarini, C., Baynes, C., Ahmed, S., Maranian, M., Healey, C. S., González-Neira, A., Pita, G., Rosario Alonso, M., Álvarez, N., Herrero, D., Tessier, D. C., Vincent, D., Bacot, F., de Santiago, I., Carroll, J., Caldas, C., Brown, M. A., Lupien, M., Kristensen, V. N., Pharoah, P. D. P., Chenevix-Trench, G., French, J. D., Easton, D. F., & Dunning, A. M. (2018). Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature communications, 916193. https://doi.org/10.1038/ncomms16193
Ghoussaini, Maya, et al. "Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation." Nature communications vol. 9 (2018): 16193. doi: https://doi.org/10.1038/ncomms16193
Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van't Veer LJ, Rutgers EJT, Couch FJ, Olson JE, Hallberg E, Vachon C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Gibson L, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Noh DY, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Benitez J, Pilar Zamora M, Perez JIA, Menéndez P, Shu XO, Lu W, Gao YT, Cai Q, Cox A, Cross SS, Reed MWR, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Lindblom A, Margolin S, Teo SH, Yip CH, Lee DSC, Wong TY, Hooning MJ, Martens JWM, Collée JM, van Deurzen CHM, Hopper JL, Southey MC, Tsimiklis H, Kapuscinski MK, Shen CY, Wu PE, Yu JC, Chen ST, Alnæs GG, Borresen-Dale AL, Giles GG, Milne RL, McLean C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Buhari SABS, Teo YY, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Brauch H, Brüning T, Koto YD, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova NV, Helbig S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RAEM, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton-Culver H, Neuhausen SL, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Rosario Alonso M, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown MA, Lupien M, Kristensen VN, Pharoah PDP, Chenevix-Trench G, French JD, Easton DF, Dunning AM. Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun. 2018 Apr 10;9:16193. doi: 10.1038/ncomms16193. PMID: 29633761; PMCID: PMC5898457.
Copy Download .nbib Format: NLM
Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content.

Oncotarget

Sandberg TP, Oosting J, van Pelt GW, Mesker WE, Tollenaar RAEM, Morreau H.
PMID: 31040931
Oncotarget. 2019 Mar 22;10(24):2416. doi: 10.18632/oncotarget.26820. eCollection 2019 Mar 22.

[This corrects the article DOI: 10.18632/oncotarget.25845.].

Cite
Sandberg TP, Oosting J, van Pelt GW, et al. Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content. Oncotarget. 2019;10(24):2416doi: 10.18632/oncotarget.26820.
Sandberg, T. P., Oosting, J., van Pelt, G. W., Mesker, W. E., Tollenaar, R. A. E. M., & Morreau, H. (2019). Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content. Oncotarget, 10(24), 2416. https://doi.org/10.18632/oncotarget.26820
Sandberg, Tessa P, et al. "Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content." Oncotarget vol. 10,24 (2019): 2416. doi: https://doi.org/10.18632/oncotarget.26820
Sandberg TP, Oosting J, van Pelt GW, Mesker WE, Tollenaar RAEM, Morreau H. Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content. Oncotarget. 2019 Mar 22;10(24):2416. doi: 10.18632/oncotarget.26820. eCollection 2019 Mar 22. PMID: 31040931; PMCID: PMC6481328.
Copy Download .nbib Format: NLM
RNF12 is regulated by AKT phosphorylation and promotes TGF-β driven breast cancer metastasis.

Cell death & disease

Huang Y, Liu S, Shan M, Hagenaars SC, Mesker WE, Cohen D, Wang L, Zheng Z, Devilee P, Tollenaar RAEM, Li Z, Song Y, Zhang L, Li D, Ten Dijke P.
PMID: 35013159
Cell Death Dis. 2022 Jan 10;13(1):44. doi: 10.1038/s41419-021-04493-y.

Transforming growth factor-β (TGF-β) acts as a pro-metastatic factor in advanced breast cancer. RNF12, an E3 ubiquitin ligase, stimulates TGF-β signaling by binding to the inhibitory SMAD7 and inducing its proteasomal degradation. How RNF12 activity is regulated and its...

Cite
Huang Y, Liu S, Shan M, et al. RNF12 is regulated by AKT phosphorylation and promotes TGF-β driven breast cancer metastasis. Cell Death Dis. 2022;13(1):44doi: 10.1038/s41419-021-04493-y.
Huang, Y., Liu, S., Shan, M., Hagenaars, S. C., Mesker, W. E., Cohen, D., Wang, L., Zheng, Z., Devilee, P., Tollenaar, R. A. E. M., Li, Z., Song, Y., Zhang, L., Li, D., & Ten Dijke, P. (2022). RNF12 is regulated by AKT phosphorylation and promotes TGF-β driven breast cancer metastasis. Cell death & disease, 13(1), 44. https://doi.org/10.1038/s41419-021-04493-y
Huang, Yongsheng, et al. "RNF12 is regulated by AKT phosphorylation and promotes TGF-β driven breast cancer metastasis." Cell death & disease vol. 13,1 (2022): 44. doi: https://doi.org/10.1038/s41419-021-04493-y
Huang Y, Liu S, Shan M, Hagenaars SC, Mesker WE, Cohen D, Wang L, Zheng Z, Devilee P, Tollenaar RAEM, Li Z, Song Y, Zhang L, Li D, Ten Dijke P. RNF12 is regulated by AKT phosphorylation and promotes TGF-β driven breast cancer metastasis. Cell Death Dis. 2022 Jan 10;13(1):44. doi: 10.1038/s41419-021-04493-y. PMID: 35013159.
Copy Download .nbib Format: NLM
ASO Visual Abstract: Patient-Related Prognostic Factors for Anastomotic Leakage, Major Complications, and Short-Term Mortality Following Esophagectomy for Cancer: A Systematic Review and Meta-Analyses.

Annals of surgical oncology

van Kooten RT, Voeten DM, Steyerberg EW, Hartgrink HH, van Berge Henegouwen MI, van Hillegersberg R, Tollenaar RAEM, Wouters MWJM.
PMID: 34570332
Ann Surg Oncol. 2021 Dec;28:740-741. doi: 10.1245/s10434-021-10785-6.

No abstract available.

Cite
van Kooten RT, Voeten DM, Steyerberg EW, et al. ASO Visual Abstract: Patient-Related Prognostic Factors for Anastomotic Leakage, Major Complications, and Short-Term Mortality Following Esophagectomy for Cancer: A Systematic Review and Meta-Analyses. Ann Surg Oncol. 2021;28:740-741doi: 10.1245/s10434-021-10785-6.
van Kooten, R. T., Voeten, D. M., Steyerberg, E. W., Hartgrink, H. H., van Berge Henegouwen, M. I., van Hillegersberg, R., Tollenaar, R. A. E. M., & Wouters, M. W. J. M. (2021). ASO Visual Abstract: Patient-Related Prognostic Factors for Anastomotic Leakage, Major Complications, and Short-Term Mortality Following Esophagectomy for Cancer: A Systematic Review and Meta-Analyses. Annals of surgical oncology, 28740-741. https://doi.org/10.1245/s10434-021-10785-6
van Kooten, Robert T, et al. "ASO Visual Abstract: Patient-Related Prognostic Factors for Anastomotic Leakage, Major Complications, and Short-Term Mortality Following Esophagectomy for Cancer: A Systematic Review and Meta-Analyses." Annals of surgical oncology vol. 28 (2021): 740-741. doi: https://doi.org/10.1245/s10434-021-10785-6
van Kooten RT, Voeten DM, Steyerberg EW, Hartgrink HH, van Berge Henegouwen MI, van Hillegersberg R, Tollenaar RAEM, Wouters MWJM. ASO Visual Abstract: Patient-Related Prognostic Factors for Anastomotic Leakage, Major Complications, and Short-Term Mortality Following Esophagectomy for Cancer: A Systematic Review and Meta-Analyses. Ann Surg Oncol. 2021 Dec;28:740-741. doi: 10.1245/s10434-021-10785-6. PMID: 34570332.
Copy Download .nbib Format: NLM
Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer.

Thrombosis research

Hanna-Sawires RG, Groen JV, Hamming A, Tollenaar RAEM, Mesker WE, Luelmo SAC, Vahrmeijer AL, Bonsing BA, Versteeg HH, Klok FA, Mieog JSD.
PMID: 34628229
Thromb Res. 2021 Aug 08;207:134-139. doi: 10.1016/j.thromres.2021.08.002. Epub 2021 Aug 08.

INTRODUCTION: Pancreatic cancer is associated with a high risk of venous thromboembolism (VTE). However, comprehensive data on incidence, timing and relevant determinants of VTE in this particular population are scarce. Current study assesses incidence, timing and predictors of VTE...

Cite
Hanna-Sawires RG, Groen JV, Hamming A, et al. Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer. Thromb Res. 2021;207:134-139doi: 10.1016/j.thromres.2021.08.002.
Hanna-Sawires, R. G., Groen, J. V., Hamming, A., Tollenaar, R. A. E. M., Mesker, W. E., Luelmo, S. A. C., Vahrmeijer, A. L., Bonsing, B. A., Versteeg, H. H., Klok, F. A., & Mieog, J. S. D. (2021). Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer. Thrombosis research, 207134-139. https://doi.org/10.1016/j.thromres.2021.08.002
Hanna-Sawires, Randa G, et al. "Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer." Thrombosis research vol. 207 (2021): 134-139. doi: https://doi.org/10.1016/j.thromres.2021.08.002
Hanna-Sawires RG, Groen JV, Hamming A, Tollenaar RAEM, Mesker WE, Luelmo SAC, Vahrmeijer AL, Bonsing BA, Versteeg HH, Klok FA, Mieog JSD. Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer. Thromb Res. 2021 Aug 08;207:134-139. doi: 10.1016/j.thromres.2021.08.002. Epub 2021 Aug 08. PMID: 34628229.
Copy Download .nbib Format: NLM
Variation in incidence, prevention and treatment of persistent air leak after lung cancer surgery.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

Hoeijmakers F, Hartemink KJ, Verhagen AF, Steup WH, Marra E, Röell WFB, Heineman DJ, Schreurs WH, Tollenaar RAEM, Wouters MWJM.
PMID: 34410339
Eur J Cardiothorac Surg. 2021 Dec 27;61(1):110-117. doi: 10.1093/ejcts/ezab376.

OBJECTIVES: Persistent air leak (PAL; >5 days after surgery) is the most common complication after pulmonary resection and associated with prolonged hospital stay and increased morbidity. Literature is contradictory about the prevention and treatment of PAL. Variation is therefore...

Cite
Hoeijmakers F, Hartemink KJ, Verhagen AF, et al. Variation in incidence, prevention and treatment of persistent air leak after lung cancer surgery. Eur J Cardiothorac Surg. 2021;61(1):110-117doi: 10.1093/ejcts/ezab376.
Hoeijmakers, F., Hartemink, K. J., Verhagen, A. F., Steup, W. H., Marra, E., Röell, W. F. B., Heineman, D. J., Schreurs, W. H., Tollenaar, R. A. E. M., & Wouters, M. W. J. M. (2021). Variation in incidence, prevention and treatment of persistent air leak after lung cancer surgery. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 61(1), 110-117. https://doi.org/10.1093/ejcts/ezab376
Hoeijmakers, Fieke, et al. "Variation in incidence, prevention and treatment of persistent air leak after lung cancer surgery." European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery vol. 61,1 (2021): 110-117. doi: https://doi.org/10.1093/ejcts/ezab376
Hoeijmakers F, Hartemink KJ, Verhagen AF, Steup WH, Marra E, Röell WFB, Heineman DJ, Schreurs WH, Tollenaar RAEM, Wouters MWJM. Variation in incidence, prevention and treatment of persistent air leak after lung cancer surgery. Eur J Cardiothorac Surg. 2021 Dec 27;61(1):110-117. doi: 10.1093/ejcts/ezab376. PMID: 34410339.
Copy Download .nbib Format: NLM
Time interval between rectal cancer resection and reintervention for anastomotic leakage and the impact of a defunctioning stoma: A Dutch population-based study.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

Warps AK, Tollenaar RAEM, Tanis PJ, Dekker JWT.
PMID: 34407272
Colorectal Dis. 2021 Nov;23(11):2937-2947. doi: 10.1111/codi.15878. Epub 2021 Sep 07.

AIM: In the Netherlands, a selective policy of faecal diversion after rectal cancer surgery is generally applied. This study aimed to evaluate the timing, type, and short-term outcomes of reoperation for anastomotic leakage after primary rectal cancer resection stratified...

Cite
Warps AK, Tollenaar RAEM, Tanis PJ, et al. Time interval between rectal cancer resection and reintervention for anastomotic leakage and the impact of a defunctioning stoma: A Dutch population-based study. Colorectal Dis. 2021;23(11):2937-2947doi: 10.1111/codi.15878.
Warps, A. K., Tollenaar, R. A. E. M., Tanis, P. J., Dekker, J. W. T. (2021). Time interval between rectal cancer resection and reintervention for anastomotic leakage and the impact of a defunctioning stoma: A Dutch population-based study. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 23(11), 2937-2947. https://doi.org/10.1111/codi.15878
Warps, Anne-Loes K, et al. "Time interval between rectal cancer resection and reintervention for anastomotic leakage and the impact of a defunctioning stoma: A Dutch population-based study." Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland vol. 23,11 (2021): 2937-2947. doi: https://doi.org/10.1111/codi.15878
Warps AK, Tollenaar RAEM, Tanis PJ, Dekker JWT. Time interval between rectal cancer resection and reintervention for anastomotic leakage and the impact of a defunctioning stoma: A Dutch population-based study. Colorectal Dis. 2021 Nov;23(11):2937-2947. doi: 10.1111/codi.15878. Epub 2021 Sep 07. PMID: 34407272.
Copy Download .nbib Format: NLM
Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort.

Translational oncology

Potjer TP, Mertens BJ, Nicolardi S, van der Burgt YE, Bonsing BA, Mesker WE, Tollenaar RA, Vasen HF.
PMID: 27267843
Transl Oncol. 2016 Jun;9(3):242-7. doi: 10.1016/j.tranon.2016.03.003.

BACKGROUND: Pancreatic cancer (PC) surveillance is currently offered to individuals with a genetic predisposition to PC, but routinely used radiological screening modalities are not entirely reliable in detecting early-stage PC or its precursor lesions. We recently identified a discriminating...

Cite
Potjer TP, Mertens BJ, Nicolardi S, et al. Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort. Transl Oncol. 2016;9(3):242-7doi: 10.1016/j.tranon.2016.03.003.
Potjer, T. P., Mertens, B. J., Nicolardi, S., van der Burgt, Y. E., Bonsing, B. A., Mesker, W. E., Tollenaar, R. A., & Vasen, H. F. (2016). Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort. Translational oncology, 9(3), 242-7. https://doi.org/10.1016/j.tranon.2016.03.003
Potjer, Thomas P, et al. "Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort." Translational oncology vol. 9,3 (2016): 242-7. doi: https://doi.org/10.1016/j.tranon.2016.03.003
Potjer TP, Mertens BJ, Nicolardi S, van der Burgt YE, Bonsing BA, Mesker WE, Tollenaar RA, Vasen HF. Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort. Transl Oncol. 2016 Jun;9(3):242-7. doi: 10.1016/j.tranon.2016.03.003. PMID: 27267843; PMCID: PMC4907893.
Copy Download .nbib Format: NLM
A Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Assay for the Relative Quantitation of Antennary Fucosylated .

Frontiers in chemistry

Rebello OD, Nicolardi S, Lageveen-Kammeijer GSM, Nouta J, Gardner RA, Mesker WE, Tollenaar RAEM, Spencer DIR, Wuhrer M, Falck D.
PMID: 32185163
Front Chem. 2020 Feb 28;8:138. doi: 10.3389/fchem.2020.00138. eCollection 2020.

Changes in the abundance of antennary fucosylated glycans in human total plasma

Cite
Rebello OD, Nicolardi S, Lageveen-Kammeijer GSM, et al. A Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Assay for the Relative Quantitation of Antennary Fucosylated . Front Chem. 2020;8:138doi: 10.3389/fchem.2020.00138.
Rebello, O. D., Nicolardi, S., Lageveen-Kammeijer, G. S. M., Nouta, J., Gardner, R. A., Mesker, W. E., Tollenaar, R. A. E. M., Spencer, D. I. R., Wuhrer, M., & Falck, D. (2020). A Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Assay for the Relative Quantitation of Antennary Fucosylated . Frontiers in chemistry, 8138. https://doi.org/10.3389/fchem.2020.00138
Rebello, Osmond D, et al. "A Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Assay for the Relative Quantitation of Antennary Fucosylated ." Frontiers in chemistry vol. 8 (2020): 138. doi: https://doi.org/10.3389/fchem.2020.00138
Rebello OD, Nicolardi S, Lageveen-Kammeijer GSM, Nouta J, Gardner RA, Mesker WE, Tollenaar RAEM, Spencer DIR, Wuhrer M, Falck D. A Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Assay for the Relative Quantitation of Antennary Fucosylated . Front Chem. 2020 Feb 28;8:138. doi: 10.3389/fchem.2020.00138. eCollection 2020. PMID: 32185163; PMCID: PMC7059190.
Copy Download .nbib Format: NLM
Tumor stroma as contributing factor in the lymph node metastases process?.

Oncotarget

Mesker WE, van Pelt GW, Tollenaar RAEM.
PMID: 30847019
Oncotarget. 2019 Jan 29;10(9):922-923. doi: 10.18632/oncotarget.26644. eCollection 2019 Jan 29.

No abstract available.

Cite
Mesker WE, van Pelt GW, Tollenaar RAEM. Tumor stroma as contributing factor in the lymph node metastases process?. Oncotarget. 2019;10(9):922-923doi: 10.18632/oncotarget.26644.
Mesker, W. E., van Pelt, G. W., & Tollenaar, R. A. E. M. (2019). Tumor stroma as contributing factor in the lymph node metastases process?. Oncotarget, 10(9), 922-923. https://doi.org/10.18632/oncotarget.26644
Mesker, Wilma E, et al. "Tumor stroma as contributing factor in the lymph node metastases process?." Oncotarget vol. 10,9 (2019): 922-923. doi: https://doi.org/10.18632/oncotarget.26644
Mesker WE, van Pelt GW, Tollenaar RAEM. Tumor stroma as contributing factor in the lymph node metastases process?. Oncotarget. 2019 Jan 29;10(9):922-923. doi: 10.18632/oncotarget.26644. eCollection 2019 Jan 29. PMID: 30847019; PMCID: PMC6398172.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 43 entries